Literature DB >> 27613868

The Oncogenic Fusion Proteins SET-Nup214 and Sequestosome-1 (SQSTM1)-Nup214 Form Dynamic Nuclear Bodies and Differentially Affect Nuclear Protein and Poly(A)+ RNA Export.

Sarah A Port1, Adélia Mendes2, Christina Valkova3, Christiane Spillner1, Birthe Fahrenkrog2, Christoph Kaether3, Ralph H Kehlenbach4.   

Abstract

Genetic rearrangements are a hallmark of several forms of leukemia and can lead to oncogenic fusion proteins. One example of an affected chromosomal region is the gene coding for Nup214, a nucleoporin that localizes to the cytoplasmic side of the nuclear pore complex (NPC). We investigated two such fusion proteins, SET-Nup214 and SQSTM1 (sequestosome)-Nup214, both containing C-terminal portions of Nup214. SET-Nup214 nuclear bodies containing the nuclear export receptor CRM1 were observed in the leukemia cell lines LOUCY and MEGAL. Overexpression of SET-Nup214 in HeLa cells leads to the formation of similar nuclear bodies that recruit CRM1, export cargo proteins, and certain nucleoporins and concomitantly affect nuclear protein and poly(A)+ RNA export. SQSTM1-Nup214, although mostly cytoplasmic, also forms nuclear bodies and inhibits nuclear protein but not poly(A)+ RNA export. The interaction of the fusion proteins with CRM1 is RanGTP-dependent, as shown in co-immunoprecipitation experiments and binding assays. Further analysis revealed that the Nup214 parts mediate the inhibition of nuclear export, whereas the SET or SQSTM1 part determines the localization of the fusion protein and therefore the extent of the effect. SET-Nup214 nuclear bodies are highly mobile structures, which are in equilibrium with the nucleoplasm in interphase and disassemble during mitosis or upon treatment of cells with the CRM1-inhibitor leptomycin B. Strikingly, we found that nucleoporins can be released from nuclear bodies and reintegrated into existing NPC. Our results point to nuclear bodies as a means of preventing the formation of potentially insoluble and harmful protein aggregates that also may serve as storage compartments for nuclear transport factors.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  CRM1; Nup214; SET; leukemia; mRNA; nuclear pore; nuclear transport; nucleus; p62 (sequestosome-1 (SQSTM1))

Mesh:

Substances:

Year:  2016        PMID: 27613868      PMCID: PMC5087727          DOI: 10.1074/jbc.M116.735340

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

1.  SQSTM1-NUP214: a new gene fusion in adult T-cell acute lymphoblastic leukemia.

Authors:  Paolo Gorello; Roberta La Starza; Danika Di Giacomo; Monica Messina; Maria Cristina Puzzolo; Barbara Crescenzi; Alessandra Santoro; Sabina Chiaretti; Cristina Mecucci
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

2.  Structural determinants and mechanism of mammalian CRM1 allostery.

Authors:  Nicole Dölker; Clement E Blanchet; Béla Voß; David Haselbach; Christian Kappel; Thomas Monecke; Dmitri I Svergun; Holger Stark; Ralf Ficner; Ulrich Zachariae; Helmut Grubmüller; Achim Dickmanns
Journal:  Structure       Date:  2013-07-11       Impact factor: 5.006

3.  Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA.

Authors:  B Wolff; J J Sanglier; Y Wang
Journal:  Chem Biol       Date:  1997-02

4.  Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies.

Authors:  Serhiy Pankiv; Trond Lamark; Jack-Ansgar Bruun; Aud Øvervatn; Geir Bjørkøy; Terje Johansen
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

5.  Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements.

Authors:  M Fornerod; J Boer; S van Baal; M Jaeglé; M von Lindern; K G Murti; D Davis; J Bonten; A Buijs; G Grosveld
Journal:  Oncogene       Date:  1995-05-04       Impact factor: 9.867

6.  Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA.

Authors:  Andreas C Woerner; Frédéric Frottin; Daniel Hornburg; Li R Feng; Felix Meissner; Maria Patra; Jörg Tatzelt; Matthias Mann; Konstanze F Winklhofer; F Ulrich Hartl; Mark S Hipp
Journal:  Science       Date:  2015-12-03       Impact factor: 47.728

7.  Leukemia-Associated Nup214 Fusion Proteins Disturb the XPO1-Mediated Nuclear-Cytoplasmic Transport Pathway and Thereby the NF-κB Signaling Pathway.

Authors:  Shoko Saito; Sadik Cigdem; Mitsuru Okuwaki; Kyosuke Nagata
Journal:  Mol Cell Biol       Date:  2016-06-15       Impact factor: 4.272

8.  Nup358, a cytoplasmically exposed nucleoporin with peptide repeats, Ran-GTP binding sites, zinc fingers, a cyclophilin A homologous domain, and a leucine-rich region.

Authors:  J Wu; M J Matunis; D Kraemer; G Blobel; E Coutavas
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

9.  SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines.

Authors:  Hilmar Quentmeier; Björn Schneider; Sonja Röhrs; Julia Romani; Margarete Zaborski; Roderick A F Macleod; Hans G Drexler
Journal:  J Hematol Oncol       Date:  2009-01-23       Impact factor: 17.388

10.  The GLFG repetitive region of the nucleoporin Nup116p interacts with Kap95p, an essential yeast nuclear import factor.

Authors:  M K Iovine; J L Watkins; S R Wente
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

View more
  8 in total

Review 1.  The roles of the nuclear pore complex in cellular dysfunction, aging and disease.

Authors:  Stephen Sakuma; Maximiliano A D'Angelo
Journal:  Semin Cell Dev Biol       Date:  2017-05-12       Impact factor: 7.727

2.  The nuclear pore proteins Nup88/214 and T-cell acute lymphatic leukemia-associated NUP214 fusion proteins regulate Notch signaling.

Authors:  Bastian Kindermann; Christina Valkova; Andreas Krämer; Birgit Perner; Christian Engelmann; Laura Behrendt; Daniel Kritsch; Berit Jungnickel; Ralph H Kehlenbach; Franz Oswald; Christoph Englert; Christoph Kaether
Journal:  J Biol Chem       Date:  2019-06-11       Impact factor: 5.157

3.  Disclosing the Interactome of Leukemogenic NUP98-HOXA9 and SET-NUP214 Fusion Proteins Using a Proteomic Approach.

Authors:  Adélia Mendes; Ramona Jühlen; Sabrina Bousbata; Birthe Fahrenkrog
Journal:  Cells       Date:  2020-07-10       Impact factor: 6.600

4.  The SQSTM1-NUP214 fusion protein interacts with Crm1, activates Hoxa and Meis1 genes, and drives leukemogenesis in mice.

Authors:  Catherine P Lavau; Waitman K Aumann; Sei-Gyung K Sze; Veerain Gupta; Katelyn Ripple; Sarah A Port; Ralph H Kehlenbach; Daniel S Wechsler
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

Review 5.  NUP214 in Leukemia: It's More than Transport.

Authors:  Adélia Mendes; Birthe Fahrenkrog
Journal:  Cells       Date:  2019-01-21       Impact factor: 6.600

6.  Chromatin-bound CRM1 recruits SET-Nup214 and NPM1c onto HOX clusters causing aberrant HOX expression in leukemia cells.

Authors:  Masahiro Oka; Sonoko Mura; Mayumi Otani; Yoichi Miyamoto; Jumpei Nogami; Kazumitsu Maehara; Akihito Harada; Taro Tachibana; Yoshihiro Yoneda; Yasuyuki Ohkawa
Journal:  Elife       Date:  2019-11-22       Impact factor: 8.140

7.  Titanium Dioxide Nanoparticles Alter the Cellular Phosphoproteome in A549 Cells.

Authors:  Mathilde Biola-Clier; Jean-Charles Gaillard; Thierry Rabilloud; Jean Armengaud; Marie Carriere
Journal:  Nanomaterials (Basel)       Date:  2020-01-21       Impact factor: 5.076

8.  Targeted CRM1-inhibition perturbs leukemogenic NUP214 fusion proteins and exerts anti-cancer effects in leukemia cell lines with NUP214 rearrangements.

Authors:  Adélia Mendes; Ramona Jühlen; Valérie Martinelli; Birthe Fahrenkrog
Journal:  Oncotarget       Date:  2020-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.